Search form

Search form

Canadian researchers found that patients who took a combination of metformin and GlaxoSmithKline's Avandia in a low dose were two-thirds less likely to develop Type 2 diabetes. The treatment appeared to prevent progression from prediabetes to full Type 2 diabetes without causing adverse effects such as heart failure or fluid retention, which are typically associated with the drugs.

Related Summaries

A higher-dose combination of linagliptin and metformin fared better than a high-dose metformin-only treatment in lowering blood glucose levels in patients with type 2 diabetes, a study presented at the American Association of Clinical Endocrinologists meeting showed. The combination treatment was also very well-tolerated in patients over 18 months, a researcher said.

A low-dose metformin/rosiglitazone treatment fared better than a placebo in improving glycemic control and insulin sensitivity in participants with impaired glucose tolerance, a study in Diabetes Care found. However, the treatment did not reduce the risk of insulin resistance and beta cell dysfunction that develop over time, experts said. The findings suggest that metformin/rosiglitazone therapy may help delay the early onset of type 2 diabetes, but not its succeeding complications, researchers added.

Canadian researchers found that patients who took a combination of metformin and GlaxoSmithKline's Avandia in a low dose were two-thirds less likely to develop Type 2 diabetes. The treatment appeared to prevent progression from prediabetes to full Type 2 diabetes without causing adverse effects such as heart failure or fluid retention, which are typically associated with the drugs.

A combination of cholesterol drug lovastatin, blood pressure treatment lisinopril and low-dose aspirin reduced the chance of heart attack and stroke by as much as 80% in high-risk patients, a study shows. The findings indicate that people do not need to take expensive, brand-name treatments to prevent heart attack or stroke, researchers said.

A combination of cholesterol drug lovastatin, blood pressure treatment lisinopril and low-dose aspirin reduced the chance of heart attack and stroke by as much as 80% in high-risk patients, a study shows. The findings indicate that people do not need to take expensive, brand-name treatments to prevent heart attack or stroke, researchers said.